CN Patent

CN1169573C — 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂

Assigned to Santen Pharmaceutical Co Ltd · Expires 2004-10-06 · 22y expired

What this patent protects

钠尿肽在眼科学领域中的新效果。用于治疗角结膜衰竭的泪液分泌促进剂或滴眼剂，它们包含作为活性组分的钠尿肽。该钠尿肽包括：心房钠尿肽(ANP)、脑钠尿肽(BNP)和C钠尿肽(CNP)。角结膜衰竭的典型实例包括：眼干涸、角膜上皮磨损和角膜溃疡。

USPTO Abstract

钠尿肽在眼科学领域中的新效果。用于治疗角结膜衰竭的泪液分泌促进剂或滴眼剂，它们包含作为活性组分的钠尿肽。该钠尿肽包括：心房钠尿肽(ANP)、脑钠尿肽(BNP)和C钠尿肽(CNP)。角结膜衰竭的典型实例包括：眼干涸、角膜上皮磨损和角膜溃疡。

Drugs covered by this patent

Patent Metadata

Patent number: CN1169573C
Jurisdiction: CN
Classification: —
Expires: 2004-10-06
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.